Table 1 Association of WDR62 expression and clinical characteristics
From: Overexpression of WDR62 is associated with centrosome amplification in human ovarian cancer
| Â | Cases | WDR62 expression | Â | |
|---|---|---|---|---|
Negative | Positive | p value | ||
Age (years) | Â | Â | Â | Â |
 <60 | 34 | 14 (41.2%) | 20 (58.8%) | 0.157 |
 ≥60 | 51 | 13 (25.5%) | 38 (74.5%) |  |
Tumor size (cm) | Â | Â | Â | Â |
 <5 | 25 | 11 (44.0%) | 14 (56.0%) | 0.132 |
 ≥5 | 60 | 16 (26.7%) | 44 (73.3%) |  |
FIGO grade | Â | Â | Â | Â |
 Low | 29 | 18 (62.1%) | 11 (37.9%) | 0.0004 |
 High | 46 | 9 (19.6%) | 37 (80.4%) |  |
FIGO stage | Â | Â | Â | Â |
 I | 14 | 9 (64.3%) | 5 (35.7%) | 0.006 |
 II | 15 | 8 (53.3%) | 7 (46.7%) |  |
 III | 18 | 6 (33.3%) | 12 (66.7%) |  |
 IV | 28 | 4 (14.3%) | 24 (85.7%) |  |